Peptide-based drugs occupy a unique and pivotal position in the pharmaceutical landscape—they are neither as structurally simple as traditional small-molecule chemicals nor as large and complex as antibodies. Yet they skillfully combine advantages from both worlds: high targeting precision with production costs lower than those of monoclonal antibodies.
Looking at market data, this sector is experiencing remarkably strong growth. The global peptide therapeutics market was valued at approximately $140.86 billion in 2025 and is projected to climb to over $294 billion by 2033. The primary engine driving this expansion is, without question, the explosive demand for GLP-1 receptor agonists—a single category projected to reach $87–101 billion in global sales by 2026, positioning it among the world's best-selling drug classes.
From a geographical perspective, North America currently holds the largest market share, backed by its mature R&D infrastructure and commercial capabilities. Meanwhile, the Asia-Pacific region is catching up at the fastest pace, emerging as the most promising growth hub for the next phase.
Taking a broader view, over 120 therapeutic peptides and protein-based drugs have received global regulatory approval to date. Peptide drugs generate annual revenues exceeding $40 billion, while biologics surpass $460 billion—together breaking the $500 billion mark. This scale alone speaks volumes about the significance of peptide therapeutics in modern medicine.
Tracing the history, the story of peptide drugs begins in 1921, when Banting and his colleagues first extracted insulin from animal pancreatic tissue, successfully administering it to a 12-year-old diabetic patient the following year. In 1923, Eli Lilly brought the first commercial insulin product to market. For the next nine decades, insulin production relied on bovine or porcine pancreases—an approach that inevitably introduced immunogenicity issues, as non-human protein sequences tend to trigger antibody responses in patients.
The real takeoff of peptide therapeutics came in the 1950s. Vincent du Vigneaud achieved the chemical synthesis of oxytocin and vasopressin, while Robert Merrifield developed solid-phase peptide synthesis—two breakthroughs that cleared the path for large-scale manufacturing. In 1982, recombinant human insulin received FDA approval as the first recombinant therapeutic protein, marking a definitive departure from animal-derived insulin. This was followed by goserelin (1989, for cancer) and enfuvirtide (2003, for HIV), which further broadened the therapeutic scope of peptide drugs.
Entering the 21st century, the field entered the fast lane—advances in design technologies, display libraries, and novel delivery systems have resulted in over 60 new peptide drugs receiving approval over the past two decades. Among them, the most landmark achievement is arguably the 2019 approval of oral semaglutide—the first orally administered GLP-1 receptor agonist. Its arrival dramatically expanded the application scenarios for peptide therapeutics and ignited a global surge in R&D enthusiasm.
Of course, peptide drugs are not without their limitations. Rapid enzymatic degradation and poor membrane permeability remain two core challenges. In response, researchers have developed a range of chemical modification strategies—cyclization, D-amino acid substitution, PEGylation, lipidation, and Fc fusion—all of which are now commonly employed techniques.
Finally, it is worth noting that AI technology is steadily penetrating the peptide R&D space. While no AI-generated peptide drug has yet received commercial approval as of 2026, the pace of progress is unmistakable—the arrival of a truly "AI-designed drug" may not be far off.